Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exscientia

Why Is Recursion Pharma Stock Surging On Monday?

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood).

Benzinga

Why This Wildcard Stock Could Be a Future Star

Recursion’s slow and steady start could lead to a bright future in biotech.

Barchart

2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

NVIDIA Invested in These 2 AI Stocks, Should You?

Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.

MarketBeat

3 Small-Cap Stocks to Invest in AI Drug Development

As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.

Barchart

Andrew Hopkins of Exscientia: the man using AI to cure disease

The British scientist’s company employs artificial intelligence to drastically cut the time of drug development

The Guardian - UK

Man goes from council estate to €470m fortune with artificial intelligence

Andrew Hopkins grew up on a council estate but described how he has since swapped that life for one in the prestigious city of Oxford after setting up his company, Exscientia

Irish Mirror

Read news from The Economist, FT, and more,
with one subscription

The man from a Welsh council estate now worth £400m thanks to an idea he had on his walk home

Andrew Hopkins has developed a biotech company called Exscientia which is revolutionising the industry

Wales Online

Exscientia -Evotec Cancer Therapy Shows Encouraging Action In Healthy Volunteers

Exscientia plc (NASDAQ:EXAI) announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist. The drug candidate is co-invented and developed through a collaboration between Exscientia and Evotec SE (NASDAQ:EVO). Topline data confirmed Exscientia’s target product profile design, including potency, high receptor selectivity, and expected low brain exposure with…

Benzinga

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times

People

Ugur Sahin

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Recursion Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.